Primary malignant melanoma of the vagina with repeated local recurrences and brain metastasis

Journal of the Chinese Medical Association

Volumn 74, Issue 8, 2011, Pages 376-379

  Lin, Li Te ^a   Liu, Chung Bin ^a   Chen, San Nung ^a   Chiang, An Jen ^a   Liou, Wen Shiung ^a,b   Yu, Ken Jen ^a,c,d  

^a KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b TZU HUI INSTITUTE OF TECHNOLOGY   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

Author keywords

Biochemotherapy; Brain metastasis; Melanoma; Vagina

Indexed keywords

ALPHA2B INTERFERON; DACARBAZINE;

ADULT; ARTICLE; BRAIN METASTASIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CASE REPORT; DISTANT METASTASIS; FEMALE; HUMAN; HUMAN TISSUE; MELANOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL EXAMINATION; SALPINGOOOPHORECTOMY; VAGINA; VAGINAL MELANOMA; VULVECTOMY;

BRAIN NEOPLASMS; FEMALE; HUMANS; INTERFERON-ALPHA; MELANOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RECOMBINANT PROTEINS; VAGINAL NEOPLASMS;

EID: 80052088527     PISSN: 17264901     EISSN: 17287731     Source Type: Journal    
DOI: 10.1016/j.jcma.2011.06.006     Document Type: Article

References (19)

1. Samolis S., Panagopoulos P., Kanellopoulos N., Papastefanou I., Karadaglis S., Katsoulis M. Primary malignant melanoma of the vagina: case report. Eur J Gynaecol Oncol 2010, 31:233-234.
2. Michael F., Mariano E., Charlotte C.S., Pamela T.S., Patricia J.E., Charles F.L., et al. Primary malignant melanoma of the vagina. Obstet Gynecol 2010, 116:1358-1365.
3. Tjalma W.A., Monagham J.M., de Barros Lopes A., Naik R., Nordin A. Primary vaginal melanoma and long-term survivors. Eur J Gynaecol Oncol 2001, 22:20-22.
4. Balch C.M., Gershenwald J.E., Soong S., Thompson J.F., Atkins M.B., Byrd D.R., et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009, 27:6199-6206.
5. Miner T.J., Delgado R., Zeisler J., Busam K., Alektiar K., Barakat R., et al. Primary vaginal melanoma: a critical analysis of therapy. Ann Surg Oncol 2004, 11:34-39.
6. Reid G.C., Schmidt R.W., Roberts J.S., Hopkins M.P., Barret R.J., Morley G.W. Primary melanoma of the vagina: a clinicopathologic analysis. Obstet. Gynecol 1989, 74:190-199.
7. Buchanan D.J., Schlaerth J., Kurosaki T. Primary vaginal melanoma: thirteen-year disease-free survival after wide local excision and review of the literature. Am J Obstet Gynecol 1998, 178:1177-1184.
8. Van Nostrand K.M., Lucci J.A., Schell M., Berman M.L., Manetta A., DiSaia P.J. Primary vaginal melanoma: improved survival with radical pelvic surgery. Gynecol Oncol 1994, 55:234-237.
9. Geisler J.P., Look K.Y., Moore D.A., Sutton G.P. Pelvic exenteration for malignant melanoma of the vagina or urethra with over 3 mm of invasion. Gynecol Oncol 1995, 59:338-341.
10. Kirkwood J.M., Strawderman M.H., Ernstoff M.S., Smith T.J., Borden E.C., Blum R.H. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996, 14:7-17.
11. Kirkwood J.M., Ibrahim J.G., Sosman J.A., Sondak V.K., Agarwala S.S., Ernstoff M.S., et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001, 19:2370-2380.
12. Simone M., Sandro P., Carlo R.R., Donato N. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 2010, 102:493-501.
13. Eggermont A.M.M., Suciu S., Santinami M., Testori A., Kruit W.H.J., Marsden J., et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 2008, 372:117-126.
14. Bottomley A., Coens C., Suciu S., Santinami M., Kruit W., Testori A., et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol 2009, 27:2916-2923.
15. Doru T.A., Thomas E.I., Neil H.R., Francesco M.M., Anna D.N., Filamer D.K., et al. Immunotherapy for melanoma: current status and perspectives. J Immunother 2010, 33:570-590.
16. Lens M.B., Eisen T.G. Systemic chemotherapy in the treatment of malignant melanoma. Expert Opin Pharmacother 2003, 4:2205-2211.
17. Ives N.J., Stowe R.L., Lorigan P., Wheatley K. Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2621 patients. J Clin Oncol 2007, 25:5426-5434.
18. Giao Q.P., Jane L.M., Vernon K.S., Jonathan S.Z. Sentinel lymph node biopsy for melanoma: indications and rationale. Cancer Control 2009, 16:234-239.
19. Morton D.L., Thompson J.F., Cochran A.J., Mozzillo N., Elashoff R., Essner R., et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 2006, 355:1307-1317.